Glenmark Life Sciences Limited (NSE: GLS)

Market Cap	140.97B
Revenue (ttm)	22.93B
Net Income (ttm)	4.47B
Shares Out	122.53M
EPS (ttm)	36.41
PE Ratio	31.60
Forward PE	26.25
Dividend	22.50 (1.96%)
Ex-Dividend Date	n/a

Volume	1,405,331
Open	1,093.00
Previous Close	1,093.00
Day's Range	1,093.00 - 1,175.00
52-Week Range	611.00 - 1,175.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Glenmark Life Sciences

Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 2,014
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GLS

Financial Performance

In 2023, GLS's revenue was 22.83 billion, an increase of 5.64% compared to the previous year's 21.61 billion. Earnings were 4.71 billion, an increase of 0.84%.